Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 113

Sort by

Sort Order Select

Journal Articles

Challenging the concept of functional high-risk myeloma through transcriptional and genetic profiling

Sina A. Beer, David A. Cairns, Charlotte Pawlyn, Amy Holroyd, Elsa Ferris, Gordon Cook, Mark Drayson, Kevin Boyd, Paula Proszek, Faith E. Davies, Ruth de Tute, Matthew Jenner, Gareth J. Morgan, Roger Owen, Michael Hubank, Richard Houlston, Graham Jackson, Martin F. Kaiser

Blood (2025) 146 (22): 2670–2680.

https://doi.org/10.1182/blood.2025029987

Published: 2025

Includes: Supplemental data

Journal Articles

Phase 3 randomized study of teclistamab plus daratumumab versus investigator’s choice of daratumumab and dexamethasone with either pomalidomide or Bortezomib (DPd/DVd) in patients (Pts) with relapsed refractory multiple myeloma (RRMM): Results of majestec-3

Blood (2025) 146 (Supplement 2): LBA-6.

https://doi.org/10.1182/blood-2025-LBA-6

Published: 2025

Journal Articles

Can a patient questionnaire (VRAT) reduce the need for ocular examinations with less frequent belantamab mafodotin combined with bortezomib and dexamethasone? the ukmra prommise d trial

Rakesh Popat, Robert Cicero, Andrew Hall, Alexandra Welsh, Charlotte Pawlyn, Ceri Bygrave, Dean Smith, Simona Degli Esposti, Daniel Larkin, Gordon Cook, Matthew Jenner, Martin Kaiser, Lydia Lee, Rashmi Chandrashekar, Michael Nathan, Heena Patel, Sadie Roberts, Sarah Brown, Christopher Parrish

Blood (2025) 146 (Supplement 1): 4065.

https://doi.org/10.1182/blood-2025-4065

Published: 2025

Journal Articles

Randomized phase II dose optimization study of inobrodib (CCS1477), in combination with pomalidomide and dexamethasone in relapsed/refractory multiple myeloma (RRMM)

Blood (2025) 146 (Supplement 1): 4035.

https://doi.org/10.1182/blood-2025-4035

Published: 2025

Journal Articles

The impact of frailty on real world outcomes for multiple myeloma patients in England – a cohort study from the uncover study group and ukmra frailty group.

Thea Chandler, Indrani Karpha, Nurunnahar Akter, Temitope Erinfolami, Hanhua Liu, Brogan Johnston, Yeong Lim, Nagesh Kalakonda, Gillian Brearton, Sally Moore, Hira Mian, Frances Seymour, Christopher Parrish, Charlotte Pawlyn, Catrin Tudur Smith, Andrew Pettitt, Gordon Cook

Blood (2025) 146 (Supplement 1): 2792.

https://doi.org/10.1182/blood-2025-2792

Published: 2025

Journal Articles

Intra-sample flow cytometry analysis identifies upregulated interleukin-6 receptor (CD126) as a potential therapeutic target in gain(1q) myeloma

Rebecca Sarsam, Carolina Valensise, Mathilda Gibson-Watt, Sarah Clarke, Andrew Parr, Stephanie Faber, Charlotte Pawlyn, John Jones, Tim Chevassut

Blood (2025) 146 (Supplement 1): 7486.

https://doi.org/10.1182/blood-2025-7486

Published: 2025

Journal Articles

First report of AI derived metrics from whole-body MRI in patients with multiple myeloma reveals unique insights into body composition and changes on therapy

Nicolas Basty, Martin Kaiser, Davide Meo, Robby Emsley, Kevin Boyd, Charlotte Pawlyn, Jessica Winfield, Alina Dragan, Simon Doran, Karen Thomas, Dow-Mu Koh, Brandon Whitcher, Christina Messiou

Blood (2025) 146 (Supplement 1): 3978.

https://doi.org/10.1182/blood-2025-3978

Published: 2025

Journal Articles

Is IMWG frailty-score-adjusted dosing the right approach to improve toxicity and outcomes in FRAIL patients? Results from the UK-MRA FiTNEss trial in newly diagnosed myeloma patients ineligible for ASCT.

Blood (2025) 146 (Supplement 1): 369.

https://doi.org/10.1182/blood-2025-369

Published: 2025

Journal Articles

Evaluating inobrodib (CCS1477) in combination with teclistamab or elranatamab in patients with Relapsed/Refractory multiple myeloma; Specific cohorts within a Phase I/IIa study evaluating inobrodib in patients with advanced hematological malignancies

Dr. Emma Searle, Tomasz Knurowski, Sarah Gooding, Victoria Campbell, Sally Moore, Aristeidis Chaidos, Jennifer Travers, Thomas Creasey, Karen Clegg, Tim Somervaille, Charlotte Pawlyn

Blood (2025) 146 (Supplement 1): 8242.

https://doi.org/10.1182/blood-2025-8242

Published: 2025

Journal Articles

The burden of myeloma treatment routes and locations on patients and families: Insights from a Pan-European survey

Eilidh Duncan, Silene ten Seldam, Diane Loening-Martens, Xavier Leleu, Charlotte Pawlyn, Séverine Wollenschneider, Katie Joyner, Kate Morgan

Blood (2025) 146 (Supplement 1): 6342.

https://doi.org/10.1182/blood-2025-6342

Published: 2025

Journal Articles

Applying computational modelling to a high-risk multiple myeloma data set to create novel risk stratification groupings

Orthi Shahzad, Richard Norris, Niels Weinhold, Charlotte Pawlyn, Brian Walker, Cody Ashby, Christopher Wardell, David Cairns, Martin Kaiser, Gordon Cook, Faith Davies, Mark Drayson, Roger Owen, Graham Jackson, Gareth Morgan, Simon Mitchell, John Jones

Blood (2025) 146 (Supplement 1): 5790.

https://doi.org/10.1182/blood-2025-5790

Published: 2025

Journal Articles

Check the brakes on IRF4!

Charlotte Pawlyn

Blood (2025) 146 (1): 8–9.

https://doi.org/10.1182/blood.2025028615

Published: 2025

Journal Articles

Evaluating the impact of CRBN mutations on response to immunomodulatory drugs and novel cereblon E3 ligase modulators in myeloma

Yakinthi Chrisochoidou, Andrea Scarpino, Salomon Morales, Shannon Martin, Sarah Bird, Yigen Li, Brian Walker, John Caldwell, Yann-Vaï Le Bihan, Charlotte Pawlyn

Blood (2025) 145 (22): 2630–2644.

https://doi.org/10.1182/blood.2024025861

Published: 2025

Includes: Supplemental data

Journal Articles

MagnetisMM-9: Efficacy and Safety of Step-up Priming Doses and Longer Dosing Intervals of Elranatamab (ELRA) in Patients with Relapsed or Refractory Multiple Myeloma (RRMM)

Matthew Pianko, Charlotte Pawlyn, Shang-Yi Huang, Tadao Ishida, Douglas W Sborov, Shinsuke Iida, Aravind Ramakrishnan, Reuben Benjamin, Rakesh Popat, Steven Schuster, Junya Kuroda, Chia-Jen Liu, Anne Philippe, Umberto Conte, Fangxin Hong, Erik Vandendries, Rafael Fonseca

Blood (2024) 144 (Supplement 1): 4743.

https://doi.org/10.1182/blood-2024-205872

Published: 2024

Journal Articles

MRD and Molecular Risk Status Help to Define Optimal Maintenance Delivery Strategies after ASCT: Long Term Outcomes of the UK MRA Myeloma XI Trial Comparing Lenalidomide to Observation

Graham Jackson, Charlotte Pawlyn, Faith E Davies, Martin F Kaiser, Ruth M de Tute, Heather McIntyre, Jeanine Richards, Sharon Jackson, Elizabeth Hodson, Anna Hockaday, Catherine Olivier, John R Jones, Matthew W. Jenner, Gordon Cook, Walter Martin Gregory, Mark Drayson, Roger G Owen, David A. Cairns, Gareth Morgan

Blood (2024) 144 (Supplement 1): 3375.

https://doi.org/10.1182/blood-2024-205871

Published: 2024

Journal Articles

IMiDs and Celmods Enhance Antigen Presentation Via MHC Class 1 - a Potential Novel Immunostimulatory Effect

Shannon Martin, Yakinthi Chrisochoidou, Andreia S. Margarido, Fernando Sialana, Jr., Salomon Morales, Marc Leiro, Yigen Li, Sarah Bird, Konstantinos Mitsopoulos, Esther Arwert, Charlotte Pawlyn

Blood (2024) 144 (Supplement 1): 3284.

https://doi.org/10.1182/blood-2024-203340

Published: 2024

Journal Articles

IMWG Frailty Score-Adjusted Therapy Delivery Reduces the Early Mortality Risk in Newly Diagnosed Tne Multiple Myeloma: Results of the UK Myeloma Research Alliance (UK-MRA) Myeloma XIV Fitness Trial

Blood (2024) 144 (Supplement 1): 673.

https://doi.org/10.1182/blood-2024-209653

Published: 2024

Journal Articles

Cost-Effectiveness of Frailty-Adjusted Therapy in Transplant Non-Eligible Patients with Newly Diagnosed Multiple Myeloma - an Economic Evaluation of the Fitness Trial

Blood (2024) 144 (Supplement 1): 385.

https://doi.org/10.1182/blood-2024-209720

Published: 2024

Journal Articles

Optimising the Duration of Therapy for Newly Diagnosed Transplant Ineligible Patients - Analysis of Long Term Follow up Data from the UK MRA Myeloma XI Trial

Charlotte Pawlyn, Faith E Davies, Gordon Cook, Heather McIntyre, Jeanine Richards, Sharon Jackson, Elizabeth Hodson, Catherine Olivier, Anna Hockaday, John R Jones, Martin F Kaiser, Matthew W. Jenner, Walter Martin Gregory, Ruth M de Tute, Roger G Owen, Mark Drayson, David A. Cairns, Gareth Morgan, Graham Jackson

Blood (2024) 144 (Supplement 1): 1987.

https://doi.org/10.1182/blood-2024-205788

Published: 2024

Journal Articles

Belantamab Mafodotin Plus Cyclophosphamide and Dexamethasone for Patients with Relapsed or Refractory Multiple Myeloma: Interim Results from the UK Myeloma Research Alliance Prommise Clinical Trial

Blood (2024) 144 (Supplement 1): 1984.

https://doi.org/10.1182/blood-2024-204055

Published: 2024

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Challenging the concept of functional high-risk myeloma through transcriptional and genetic profiling

Phase 3 randomized study of teclistamab plus daratumumab versus investigator’s choice of daratumumab and dexamethasone with either pomalidomide or Bortezomib (DPd/DVd) in patients (Pts) with relapsed refractory multiple myeloma (RRMM): Results of majestec-3

Can a patient questionnaire (VRAT) reduce the need for ocular examinations with less frequent belantamab mafodotin combined with bortezomib and dexamethasone? the ukmra prommise d trial

Randomized phase II dose optimization study of inobrodib (CCS1477), in combination with pomalidomide and dexamethasone in relapsed/refractory multiple myeloma (RRMM)

The impact of frailty on real world outcomes for multiple myeloma patients in England – a cohort study from the uncover study group and ukmra frailty group.

Intra-sample flow cytometry analysis identifies upregulated interleukin-6 receptor (CD126) as a potential therapeutic target in gain(1q) myeloma

First report of AI derived metrics from whole-body MRI in patients with multiple myeloma reveals unique insights into body composition and changes on therapy

Is IMWG frailty-score-adjusted dosing the right approach to improve toxicity and outcomes in FRAIL patients? Results from the UK-MRA FiTNEss trial in newly diagnosed myeloma patients ineligible for ASCT.

Evaluating inobrodib (CCS1477) in combination with teclistamab or elranatamab in patients with Relapsed/Refractory multiple myeloma; Specific cohorts within a Phase I/IIa study evaluating inobrodib in patients with advanced hematological malignancies

The burden of myeloma treatment routes and locations on patients and families: Insights from a Pan-European survey

Applying computational modelling to a high-risk multiple myeloma data set to create novel risk stratification groupings

Check the brakes on IRF4!

Evaluating the impact of CRBN mutations on response to immunomodulatory drugs and novel cereblon E3 ligase modulators in myeloma

MagnetisMM-9: Efficacy and Safety of Step-up Priming Doses and Longer Dosing Intervals of Elranatamab (ELRA) in Patients with Relapsed or Refractory Multiple Myeloma (RRMM)

MRD and Molecular Risk Status Help to Define Optimal Maintenance Delivery Strategies after ASCT: Long Term Outcomes of the UK MRA Myeloma XI Trial Comparing Lenalidomide to Observation

IMiDs and Celmods Enhance Antigen Presentation Via MHC Class 1 - a Potential Novel Immunostimulatory Effect

IMWG Frailty Score-Adjusted Therapy Delivery Reduces the Early Mortality Risk in Newly Diagnosed Tne Multiple Myeloma: Results of the UK Myeloma Research Alliance (UK-MRA) Myeloma XIV Fitness Trial

Cost-Effectiveness of Frailty-Adjusted Therapy in Transplant Non-Eligible Patients with Newly Diagnosed Multiple Myeloma - an Economic Evaluation of the Fitness Trial

Optimising the Duration of Therapy for Newly Diagnosed Transplant Ineligible Patients - Analysis of Long Term Follow up Data from the UK MRA Myeloma XI Trial

Belantamab Mafodotin Plus Cyclophosphamide and Dexamethasone for Patients with Relapsed or Refractory Multiple Myeloma: Interim Results from the UK Myeloma Research Alliance Prommise Clinical Trial

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only